Indication Added

25 changes from the current 90-day window.

Indication Added

Pluvicto

Novartis Pharmaceuticals

Indication Added: Metastatic prostate carcinoma.

View drug
Indication Added

Pluvicto

Novartis Pharmaceuticals

Indication Added: Metastatic prostate carcinoma.

View drug
Indication Added

Pluvicto

ADVANCED ACCELE

Indication Added: Metastatic prostate carcinoma.

View drug